🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "huge turning point" in the fight against superbug strains of the infection, according to scientists.

A Global Public Health Issue

Cases of gonorrhoea are escalating around the world, with figures suggesting over 82 million new cases each year. Especially elevated rates are seen in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, the spread of superbugs and the very limited treatment choices currently available.”

Public health authorities are deeply concerned about the rise in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Gain Clearance

One new antibiotic, alternatively called a brand name, was cleared by the US FDA in recent days for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists anticipate that specific application of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in the same week. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment was the result of a innovative non-profit model for antibiotic development. The non-profit organisation GARDP partnered with the drug firm its industry partner to see it through.

“This authorization marks a huge turning point in the management of highly resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Research Study Outcomes and Worldwide Availability

As per results detailed in a prominent scientific publication, the new drug successfully treated the vast majority of cases of the STI. This establishes an comparable level with the current standard treatment, which combines a dual-drug approach. The research included hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals directly involved have voiced hope. Access to a single-dose, oral treatment of this kind is described as a "revolutionary step" for public health efforts. This is viewed as vital to alleviate the strain of the disease for individuals and to halt the transmission of extremely resistant gonorrhoea worldwide.